Download PDF
Thromb Haemost 1997; 78(01): 334-338
DOI: 10.1055/s-0038-1657548
Oral contraceptives and thrombotic disease
Schattauer GmbH Stuttgart

Oral Contraceptives and Myocardial Infarction: New Evidence Leaves Unanswered Questions

Margaret Thorogood
London School of Hygiene & Tropical Medicine, London, UK
› Author Affiliations
Further Information

Publication History

Publication Date:
12 July 2018 (online)

  PDF Download  Permissions and Reprints
 

  • References

  • 1 Rosenberg L, Palmer JR, Leso SM, Shapiro S. Oral contraceptive use and the risk of myocardial infarction. Am J Epidemiol 1990; 131: 1009-1016
    CrossrefPubMedGoogle Scholar
  • 2 Thorogood M, Mann J, Murphy M, Vessey M. Is oral contraceptive use still associated with an increased risk of fatal myocardial infarction? Report of a case-control study. Br J Obstet Gynaecol 1991; 98: 1245-1253
    CrossrefPubMedGoogle Scholar
  • 3 Jensen G, Nyboe J, Appleyard M, Schnohr P. Risk factors for acute myocardial infarction in Copenhagen 11: Smoking alcohol intake physicalctivity obesity, oral contraception, diabetes, lipids, and blood pressure. Eur Heart J 1991; 12: 298-308
    CrossrefPubMedGoogle Scholar
  • 4 D’Avanzo B, La VecchiaC, Negri E, Parazzini F, Franceschi S. Oral contraceptive use and risk of myocardial infarction: an Italian case control study. J Epidemiol Community Health 1994; 48: 324-325
    CrossrefPubMedGoogle Scholar
  • 5 Lewis MA, Spitzer WO, Heinemann LA, MacRae KD, Bruppacher R, Thorogood M. on behalf of Transnational Research Group on Oral Contraceptives and the Health of Young Women Third generation oral contraceptives and risk of myocardial infarction: an international case-control study. Br Med J 1996; 312: 88-90
    CrossrefPubMedGoogle Scholar
  • 6 Sidney S, Petitti DB, Quesenberry CP, Klatskey AL, Ziel HK, Wolf S. Myocardial Infarction in Users of Low-Dose Oral Contraceptives. Obstet Gynecol 1996; 88: 939-944
    CrossrefPubMedGoogle Scholar
  • 7 Slone D, Shapiro S, Kaufman DW, Rosenberg L, Mietinnen OS, Stolley PD. Risk of myocardial infarction in relation to current and discontinued use of oral contraceptives. N Engl J Med 1981; 305: 420-424
    CrossrefPubMedGoogle Scholar
  • 8 Ananijevic-Panday J, Vlajinac H. Myocardial infarction in young women with reference to oral contraceptive use. Internat J Epidemiol 1989; 18: 585-588
    CrossrefPubMedGoogle Scholar
  • 9 Poulter N et al for the writing committee of the World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Venous thromboembolic disease and combined oral contraceptives: results of international multi centre case-control study. Lancet 1995; 346: 1575-1582
    CrossrefPubMedGoogle Scholar
  • 10 Meirik O et al on behalf of the World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Effect of different progestagens in low oestrogen oral contraceptive on venous thromboembolic disease. Lancet 1995; 326: 1575-1582
    PubMedGoogle Scholar
  • 11 Spitzer WO, Lewis MA, Heinemann JA, Thorogood M, MacRae KD. on behalf of Transnational Research Group on Oral Contraceptives and the Health of Young Women. Br Med J 1996; 312: 38-48
    CrossrefPubMedGoogle Scholar
  • 12 Bloemenkamp KWM, Rosendaal FR, Helmerhurst FM, Buller HR, Vandenbroucke JP. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third generation progestagen. Lancet 1995; 346: 1593-1596
    CrossrefPubMedGoogle Scholar
  • 13 Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis C. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with different progestogen components. Lancet 1995; 346: 1589-1593
    CrossrefPubMedGoogle Scholar
  • 14 Jick H, Jick SS, Myers W. Risk of acute myocardial infarction and low-dose combined oral contraceptives. Lancet 1996; 347: 627-628
    PubMedGoogle Scholar